Abstracts tagged "glucocorticoids and treatment"

Abstract Number: 2830 • 2019 ACR/ARP Annual Meeting
Treatment Delays Associated with Prior Authorization for Infusible Medications: A Cohort Study
Zachary Wallace¹, Tyler Harkness ¹, Xiaoqing Fu ¹, John Stone ², Hyon K. Choi ³ and Rochelle Walensky ¹, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Boston, MA
Background/Purpose: Prior authorizations (PA) are commonly required by health payers as cost-containment strategies for expensive medications, including infused biologics. In rheumatology, these medications are frequently…
Abstract Number: 806 • 2017 ACR/ARHP Annual Meeting
Epidemiological Study of Giant Cell Arteritis Using a Japanese Administrative Database
Eishi Uechi and Kiyohide Fushimi, Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan
Background/Purpose: The giant cell arteritis (GCA) management requires the administration of high-dose glucocorticoid (GC) at the introduction remission and the gradual reduction of the dosage.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].